Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The Health Costs of Cost Sharing.
Q J Econ
November 2024
University of California, Berkeley School of Public Health and National Bureau of Economic Research, United States.
Article Synopsis
- The study investigates the health consequences of sudden medication interruptions due to arbitrary price changes in Medicare’s drug budget for 65-year-olds, revealing significant adverse effects on mortality.
- A decrease of $100 in monthly budget leads to a 13.9% increase in mortality risk, highlighting the vulnerability of patients who are unaware of the serious consequences of stopping medications.
- Machine learning identifies high-risk patients who disproportionately reduce usage of critical drugs, countering standard economic predictions and demonstrating that cost-sharing strategies can be inefficient and harmful to patient health.
Patterns of healthcare utilization according to health equity determinants during the first year of the pandemic at Johns Hopkins Medicine.
JAMIA Open
December 2024
Johns Hopkins Whiting School of Engineering, Institute for Computational Medicine, Baltimore, MD 21218, United States.
Article Synopsis
- The study analyzed the impact of rapid telehealth adoption due to COVID-19 on healthcare utilization at Johns Hopkins Medicine, focusing on video, phone, and in-person visits between March 2019 and December 2020.
- Findings revealed a significant 39% drop in patient-provider visits during the early pandemic phase and a 24% drop later in 2020, indicating a shift in care delivery methods.
- The research identified 21 groups based on health equity determinants experiencing varying degrees of visit drops, showing certain demographics like older adults and specific specialties were more affected than others.
Socioeconomic Barriers to Receiving Early Salvage Radiotherapy for Locally Advanced Prostate Adenocarcinoma: A Retrospective Single-Center Study.
Cureus
September 2024
Radiation Oncology, University of California San Francisco Medical Center, San Francisco, USA.
Article Synopsis
- The study identified factors that delay the start of salvage radiation therapy in prostate cancer patients post-prostatectomy, specifically focusing on PSA levels.
- It analyzed data from 81 patients treated between 2011 and 2022, noting that insurance type significantly influenced the timing of treatment initiation, with HMO and PPO patients more likely to experience delays.
- The findings highlight the importance of PSA monitoring and access to timely care, especially for patients with certain insurance plans, suggesting that healthcare policies may impact treatment outcomes.
First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting.
J Nephrol
November 2024
Department of Renal Medicine, University College London, London, UK.
Article Synopsis
- Finerenone is a non-steroidal mineralocorticoid receptor antagonist that shows promise in improving kidney and cardiovascular health for patients with chronic kidney disease (CKD) related to type 2 diabetes (T2D), as highlighted in the ongoing FINE-REAL study.
- The study, which started in June 2022 and will continue until January 2028, involves a diverse group of patients from different healthcare settings, with a total of 556 enrolled and a median follow-up of 7 months noted by the analysis cutoff on June 13, 2023.
- Findings indicate that a significant percentage of patients were on other kidney-protective medications when starting fineren
COPD treatment ratio: a measure for improving COPD population health.
Am J Manag Care
September 2024
Pharmacy Quality Alliance, 5911 Kingstowne Village Pkwy, Ste 130, Alexandria, VA 22315. Email:
Objectives: Despite chronic obstructive pulmonary disease (COPD) being a leading cause of death in the US, there are few COPD measures in current quality programs. The objective of this study was to assess the validity and applicability of the COPD treatment ratio (CTR) as a surrogate marker of COPD exacerbation risk for use in quality measurement. CTR is defined as the ratio of COPD maintenance medications to all COPD medications (maintenance and rescue).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!